Telaprevir + Peginterferon and Ribavirin: phase 2a study in coinfected patients on HAART Reported at CROI March 2 2011
Reported by Jules Levin
This is a small phase 2a study but provides information on the use of telaprevir with HAART. Of note only efavirenz or Reyataz/r based regimens were studied in this trial: other PIS have too much drug interaction with telaprevir and the drug interaction study with raltegravir has not been conducted yet but is planned soon. The safety looked fine, no serious rashes, at week 4 as you can see in this chart below 75% on EFV 7 64% on Reyataz had undetectable viral load. At week 12 75% on EFV had undetectable HCV & one patient of Reyataz became detectable so 57% were undetectable, so the numbers of patients are small and its difficult to draw too many conclusions but the data suggests good responses for coinfected patients in this study. A link to the oral slide show is below to hear the actual presentation.
